Halozyme Therapeutics is a biopharmaceutical company that develops and commercializes proprietary drug delivery technologies and devices to improve patient experiences and treatment outcomes. The company's core platform, ENHANZE, uses a recombinant human hyaluronidase enzyme to temporarily break down tissue barriers, enabling rapid subcutaneous delivery of biologics and other therapeutics that traditionally required intravenous administration—reducing treatment burden and enabling home-based care. Halozyme generates revenue through upfront licensing fees, milestone payments, bulk enzyme sales, and royalties from partner products, with a portfolio including collaborations with major pharmaceutical companies like Roche, Janssen, and Pfizer that have led to multiple approved commercial products, as well as proprietary products including a hyaluronidase formulation and a subcutaneous testosterone option.